169 related articles for article (PubMed ID: 35869560)
21.
Akbari M; Abedin Do A; Yassaee F; Mirfakhraie R
Rep Biochem Mol Biol; 2019 Apr; 8(1):21-24. PubMed ID: 31334283
[TBL] [Abstract][Full Text] [Related]
22. Tryptophan 2,3-Dioxygenase-2 in Uterine Leiomyoma: Dysregulation by MED12 Mutation Status.
Hutchinson AP; Yin P; Neale I; Coon JS; Kujawa SA; Liu S; Bulun SE
Reprod Sci; 2022 Mar; 29(3):743-749. PubMed ID: 35064560
[TBL] [Abstract][Full Text] [Related]
23. MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma.
Bertsch E; Qiang W; Zhang Q; Espona-Fiedler M; Druschitz S; Liu Y; Mittal K; Kong B; Kurita T; Wei JJ
Mod Pathol; 2014 Aug; 27(8):1144-53. PubMed ID: 24390224
[TBL] [Abstract][Full Text] [Related]
24. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.
Nagai K; Asano R; Sekiguchi F; Asai-Sato M; Miyagi Y; Miyagi E
Am J Obstet Gynecol; 2023 Feb; 228(2):207.e1-207.e9. PubMed ID: 36150519
[TBL] [Abstract][Full Text] [Related]
25. Med12 gain-of-function mutation causes leiomyomas and genomic instability.
Mittal P; Shin YH; Yatsenko SA; Castro CA; Surti U; Rajkovic A
J Clin Invest; 2015 Aug; 125(8):3280-4. PubMed ID: 26193636
[TBL] [Abstract][Full Text] [Related]
26. Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas.
Kämpjärvi K; Park MJ; Mehine M; Kim NH; Clark AD; Bützow R; Böhling T; Böhm J; Mecklin JP; Järvinen H; Tomlinson IP; van der Spuy ZM; Sjöberg J; Boyer TG; Vahteristo P
Hum Mutat; 2014 Sep; 35(9):1136-41. PubMed ID: 24980722
[TBL] [Abstract][Full Text] [Related]
27. Prevalence and clinical significance of mediator complex subunit 12 mutations in 362 Han Chinese samples with uterine leiomyoma.
Wu J; Zou Y; Luo Y; Guo JB; Liu FY; Zhou JY; Zhang ZY; Wan L; Huang OP
Oncol Lett; 2017 Jul; 14(1):47-54. PubMed ID: 28693134
[TBL] [Abstract][Full Text] [Related]
28. Cellular kinetics of
Serna VA; Wu X; Qiang W; Thomas J; Blumenfeld ML; Kurita T
Endocr Relat Cancer; 2018 Jul; 25(7):747-759. PubMed ID: 29700012
[TBL] [Abstract][Full Text] [Related]
29. Novel MED12 gene somatic mutations in women from the Southern United States with symptomatic uterine fibroids.
Halder SK; Laknaur A; Miller J; Layman LC; Diamond M; Al-Hendy A
Mol Genet Genomics; 2015 Apr; 290(2):505-11. PubMed ID: 25325994
[TBL] [Abstract][Full Text] [Related]
30. Detection of MED12 mutations in mesenchymal components of uterine adenomyomas.
Kito M; Maeda D; Kudo-Asabe Y; Tamura D; Makino K; Sageshima M; Nanjo H; Terada Y; Goto A
Hum Pathol; 2021 Mar; 109():31-36. PubMed ID: 33259844
[TBL] [Abstract][Full Text] [Related]
31. Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors.
Je EM; Kim MR; Min KO; Yoo NJ; Lee SH
Int J Cancer; 2012 Sep; 131(6):E1044-7. PubMed ID: 22532225
[TBL] [Abstract][Full Text] [Related]
32. The study of MED12 gene mutations in uterine leiomyomas from Iranian patients.
Sadeghi S; Khorrami M; Amin-Beidokhti M; Abbasi M; Kamalian Z; Irani S; Omrani M; Azmoodeh O; Mirfakhraie R
Tumour Biol; 2016 Feb; 37(2):1567-71. PubMed ID: 26298726
[TBL] [Abstract][Full Text] [Related]
33. MED12 exon 2 mutation is uncommon in intravenous leiomyomatosis: clinicopathologic features and molecular study.
Wang L; Hu S; Xin F; Zhao H; Li G; Ran W; Xing X; Wang J
Hum Pathol; 2020 May; 99():36-42. PubMed ID: 32240666
[TBL] [Abstract][Full Text] [Related]
34. MED12 is frequently mutated in ovarian and other adnexal leiomyomas.
Li Z; Maeda D; Kudo-Asabe Y; Tamura D; Nanjo H; Hayashi A; Ikemura M; Fukayama M; Goto A
Hum Pathol; 2018 Nov; 81():89-95. PubMed ID: 29944972
[TBL] [Abstract][Full Text] [Related]
35. Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19.
Park MJ; Shen H; Spaeth JM; Tolvanen JH; Failor C; Knudtson JF; McLaughlin J; Halder SK; Yang Q; Bulun SE; Al-Hendy A; Schenken RS; Aaltonen LA; Boyer TG
J Biol Chem; 2018 Mar; 293(13):4870-4882. PubMed ID: 29440396
[TBL] [Abstract][Full Text] [Related]
36. High-resolution melting analysis of MED12 mutations in uterine leiomyomas in Chinese patients.
Wang H; Ye J; Qian H; Zhou R; Jiang J; Ye L
Genet Test Mol Biomarkers; 2015 Mar; 19(3):162-6. PubMed ID: 25615570
[TBL] [Abstract][Full Text] [Related]
37. Prevalence and clinical significance of co-existing mutations in
Jamaluddin MFB; Nagendra PB; Ko YA; Bajwa P; Scott RJ; Nahar P; Tanwar PS
Front Reprod Health; 2023; 5():1081092. PubMed ID: 37113812
[TBL] [Abstract][Full Text] [Related]
38. Factors affecting the loss of MED12-mutated leiomyoma cells during in vitro growth.
Bloch J; Holzmann C; Koczan D; Helmke BM; Bullerdiek J
Oncotarget; 2017 May; 8(21):34762-34772. PubMed ID: 28410233
[TBL] [Abstract][Full Text] [Related]
39. Analysis of
Lee M; Cheon K; Chae B; Hwang H; Kim HK; Chung YJ; Song JY; Cho HH; Kim JH; Kim MR
Int J Med Sci; 2018; 15(2):124-128. PubMed ID: 29333096
[TBL] [Abstract][Full Text] [Related]
40. MED12 exon 2 mutations in histopathological uterine leiomyoma variants.
Mäkinen N; Vahteristo P; Kämpjärvi K; Arola J; Bützow R; Aaltonen LA
Eur J Hum Genet; 2013 Nov; 21(11):1300-3. PubMed ID: 23443020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]